{"id":1413,"date":"2026-09-27T16:34:38","date_gmt":"2026-09-27T08:34:38","guid":{"rendered":"http:\/\/www.puriactives.com\/en\/?p=1413"},"modified":"2026-09-27T16:34:38","modified_gmt":"2026-09-27T08:34:38","slug":"nanoactive-ela-nano-encapsulated-ellagic-acid","status":"publish","type":"post","link":"http:\/\/www.puriactives.com\/en\/?p=1413","title":{"rendered":"NanoActive ELA \u2014 Nano-Encapsulated Ellagic Acid"},"content":{"rendered":"

PuriActives\u00ae NanoActive Nano-Encapsulation Platform \u00b7<\/p>\n

PURIPHARM CO., LTD.<\/p>\n

NanoActive ELA \u2014 Nano-Encapsulated Ellagic Acid<\/h2>\n

Unlocking the multi-dimensional skincare and haircare potential<\/p>\n

of ellagic acid through nano-delivery<\/p>\n

INCI NAME: ELLAGIC ACID \uff5c CAS 476-66-4<\/p>\n

01 \u00b7 WHY ELLAGIC ACID \u00b7 THE MOLECULE<\/p>\n

A natural polyphenol active, validated again and again<\/h2>\n

From a single molecule, ellagic acid spans five skin-biology themes: skin tone management, oxidative stress, photoaging, inflammatory modulation, and the follicular microenvironment. Since its first cosmetic-science publication in 2000, skin- and hair-related evidence for ellagic acid has accumulated across four levels: in-vitro enzymology, cell models, animal models, and human randomized controlled trials.<\/p>\n

Skin tone management<\/h3>\n

Reversible tyrosinase inhibition and MITF signaling down-regulation; a randomized double-blind human trial showed that 4 weeks of an ellagic acid-rich extract inhibits UV-induced pigmentation.<\/p>\n

Oxidative stress defense<\/h3>\n

Direct radical scavenging plus up-regulation of the endogenous Nrf2 \/ HO-1 \/ SOD antioxidant system, protecting keratinocytes and fibroblasts from UV oxidative damage.<\/p>\n

Photoaging protection<\/h3>\n

In UVB animal models, reduces wrinkle formation and epidermal thickening, inhibits MMP secretion and collagen degradation, and down-regulates inflammatory signals such as IL-1\u03b2 and IL-6.<\/p>\n

Scalp & follicular microenvironment<\/h3>\n

Inhibits DHT-induced ferroptosis in dermal papilla cells and activates Wnt\/\u03b2-catenin signaling.<\/p>\n

Sources \u2014 Kasai et al., J Nutr Sci Vitaminol 2006 \u00b7 Hseu et al., Food Chem Toxicol 2012 \u00b7 Bae et al., Exp Dermatol 2010 \u00b7 Fu et al., J Ethnopharmacol 2024<\/p>\n

02 \u00b7 MOLECULAR PROFILE \u00b7 THE SCIENCE<\/p>\n

Ellagic acid: a highly conjugated polyphenolic dilactone<\/h2>\n

<\/p>\n\n\n\n\n\n\n\n\n\n
Common name<\/td>\nEllagic acid<\/td>\n<\/tr>\n
INCI<\/td>\nELLAGIC ACID<\/td>\n<\/tr>\n
CAS No.<\/td>\n476-66-4<\/td>\n<\/tr>\n
Formula \/ MW<\/td>\nC\u2081\u2084H\u2086O\u2088 \/ 302.19 g\u00b7mol\u207b\u00b9<\/td>\n<\/tr>\n
Chemical class<\/td>\nHydrolysable-tannin-derived polyphenolic dilactone<\/td>\n<\/tr>\n
IUPAC<\/td>\n2,3,7,8-Tetrahydroxychromeno[5,4,3-cde]chromene-5,10-dione<\/td>\n<\/tr>\n
Natural sources<\/td>\nPomegranate, berries, nuts, Chinese gallnut, etc.<\/td>\n<\/tr>\n<\/tbody>\n<\/table>\n

Structure\u2013activity relationship<\/h3>\n

\u25cf 4 phenolic hydroxyls: donate hydrogen to quench free radicals \u2014 the basis of antioxidant activity<\/p>\n

\u25cf Vicinal phenolic hydroxyls: chelate metal ions such as Cu\u00b2\u207a, acting on the tyrosinase active center<\/p>\n

\u25cf Highly conjugated rigid scaffold + two lactone rings: both electron-donor and acceptor sites, strong redox activity<\/p>\n

Sources \u2014 R\u00edos et al., Planta Med 2018;84:1068\u20131093 \u00b7 Castellacci & Bergonzi, Molecules 2025;30:4493 \u00b7 Mantzourani et al., Separations 2024;11:174<\/p>\n

03 \u00b7 MULTI-DIMENSIONAL SKIN BIOLOGY \u00b7 THE SCIENCE<\/p>\n

One molecule, five dimensions<\/h2>\n

<\/p>\n

Each of the five dimensions is supported by research in skin, scalp, or their cell models \u2014 the following chapters walk through them one by one.<\/p>\n

04 \u00b7 SKIN TONE MANAGEMENT (I) \u00b7 SKIN TONE<\/p>\n

Targeting tyrosinase: melanin control from the active center up<\/h2>\n

<\/p>\n

Tyrosinase inhibition\u3000IC\u2085\u2080 = 0.2 \u00b1 0.05 mM<\/b><\/p>\n

In-vitro mushroom tyrosinase kinetics: ellagic acid is a reversible, mixed-type inhibitor whose binding relies on hydrogen bonds and electrostatic interactions (Huang et al., 2019)<\/p>\n

Consistent evidence from enzymology to cells and animal models<\/h3>\n

\u25cf A defined site of action:<\/b> ellagic acid chelates the Cu\u00b2\u207a at the tyrosinase active center \u2014 reversible inhibition that does not damage melanocytes (Shimogaki et al., 2000)<\/p>\n

\u25cf Cellular level:<\/b> melanogenesis suppressed in B16 melanoma cells; removing ellagic acid restores melanin synthesis, indicating a non-cytotoxic mechanism (Shimogaki et al., 2000)<\/p>\n

\u25cf Animal level:<\/b> inhibits UV-induced skin pigmentation in the brown guinea pig model (Shimogaki et al., 2000; Yoshimura et al., 2005)<\/p>\n

\u25cf Kinetic support:<\/b> ellagic acid can enter the melanin biosynthesis pathway directly and be oxidized by tyrosinase, interfering with the melanization process (Ortiz-Ruiz et al., 2016)<\/p>\n

Sources \u2014 Huang et al., J Food Biochem 2019;43:e12996 \u00b7 Shimogaki et al., Int J Cosmet Sci 2000;22:291\u2013303 \u00b7 Yoshimura et al., Biosci Biotechnol Biochem 2005;69:2368\u20132373 \u00b7 Ortiz-Ruiz et al., J Dermatol Sci 2016;82:115\u2013122<\/p>\n

05 \u00b7 SKIN TONE MANAGEMENT (II) \u00b7 SKIN TONE<\/p>\n

A complete chain from signaling pathways to human evidence<\/h2>\n

<\/p>\n

Human-level skin tone evidence<\/h3>\n

2006\u3000Randomized double-blind placebo-controlled trial<\/b> \u2014 oral ellagic acid-rich (90%) pomegranate extract at 100 \/ 200 mg\u00b7d\u207b\u00b9 \u00d7 4 weeks inhibited UV-induced skin pigmentation (Kasai et al.)<\/p>\n

2008\u3000Randomized prospective open study in melasma<\/b> \u2014 30 subjects; topical 1% ellagic acid formulation reduced melanin levels (Ertam et al.)<\/p>\n

2013\u3000Comparative evaluation vs. 4% hydroquinone<\/b> \u2014 a formula of 0.5% ellagic acid + 0.1% salicylic acid was comparable to 4% hydroquinone in reducing the appearance of dark spots, with good tolerability (Dahl et al.)<\/p>\n

Mechanism verification:<\/b> the autophagy inhibitor 3-MA or LC3 silencing markedly weakens ellagic acid’s anti-melanogenic effect; an in-vivo zebrafish model confirms inhibition of tyrosinase activity and endogenous pigmentation (Yang et al., 2021).<\/p>\n

Cosmetic-language translation: improving dull skin tone \u00b7 evening skin tone \u00b7 enhancing skin radiance \u00b7 reducing the appearance of dark spots \u00b7 improving photodamage-related uneven tone<\/p>\n

Sources \u2014 Yang et al., Biochem Pharmacol 2021;185:114454 \u00b7 Kasai et al., J Nutr Sci Vitaminol 2006;52:383\u2013388 \u00b7 Ertam et al., J Dermatol 2008;35:570\u2013574 \u00b7 Dahl et al., J Drugs Dermatol 2013;12:52\u201358<\/p>\n

06 \u00b7 OXIDATIVE STRESS DEFENSE \u00b7 ANTIOXIDANT<\/p>\n

From radical scavenging to activating the endogenous antioxidant system<\/h2>\n

<\/p>\n

DPPH radical scavenging\u3000IC\u2085\u2080 = 4.86 \u00b5M<\/b><\/p>\n

Measured by in-vitro chemiluminescence assay (Muddathir et al., 2013)<\/p>\n

Keratinocytes: UVA oxidative stress model<\/h3>\n

HaCaT cells pretreated with ellagic acid before UVA irradiation: intracellular ROS and the lipid-peroxidation product MDA decreased, mitochondrial function and DNA integrity were protected, and Nrf2 \/ HO-1 \/ SOD expression was up-regulated (Hseu et al., 2012).<\/p>\n

Fibroblasts: UVB oxidative stress model<\/h3>\n

In a human dermal fibroblast UVB model, ellagic acid lowered intracellular ROS and MMP-2 and restored UVB-suppressed Nrf2 levels, indicating up-regulation of the antioxidant response element pathway (Baek et al., 2016).<\/p>\n

Ellagic acid’s antioxidant action is not single-point scavenging: beyond direct radical quenching by phenolic hydroxyls, it up-regulates the endogenous antioxidant enzyme system via the Nrf2 \/ ARE axis \u2014 a dual-layer “direct scavenging + systemic defense” mechanism.<\/p>\n

Formulation translation: antioxidant serums \u00b7 urban defense \u00b7 anti-pollution care \u00b7 the mechanistic basis for daytime defense products<\/p>\n

Sources \u2014 Hseu et al., Food Chem Toxicol 2012;50:1245\u20131255 \u00b7 Baek et al., Korean J Physiol Pharmacol 2016;20:269\u2013277 \u00b7 Muddathir et al., J Wood Sci 2013;59:426\u2013431 \u00b7 Yang et al., Biochem Pharmacol 2021;185:114454<\/p>\n

07 \u00b7 PHOTOAGING PROTECTION \u00b7 PHOTOAGING<\/p>\n

Breaking the UV \u2192 ROS \u2192 MAPK \/ AP-1 \u2192 MMP damage cascade<\/h2>\n

<\/p>\n

UVB hairless mouse model (Bae et al., 2010)<\/h3>\n

\u25cf<\/b> Ellagic acid treatment reduced UVB-induced wrinkle formation and epidermal thickening<\/p>\n

\u25cf<\/b> Inhibited MMP secretion and collagen degradation, and down-regulated inflammatory factors including IL-1\u03b2 and IL-6<\/p>\n

\u25cf<\/b> Indicates ellagic acid acts simultaneously on the three photoaging links: oxidation \u2014 inflammation \u2014 matrix degradation<\/p>\n

<\/p>\n

Positive support for matrix synthesis:<\/b> in human dermal fibroblasts, ellagic acid \u2014 alone or combined with retinoic acid \u2014 promotes collagen and elastin production (Duckworth et al., 2023).<\/p>\n

Sources \u2014 Bae et al., Exp Dermatol 2010;19:e182\u2013e190 \u00b7 Abd-Elghany & Mohamad, ACS Omega 2023;8:16620\u201316629 \u00b7 Duckworth et al., Biomed Mater Eng 2023;34:473\u2013480<\/p>\n

08 \u00b7 SOOTHING & SKIN HOMEOSTASIS \u00b7 SOOTHING<\/p>\n

Bidirectional regulation of oxidation and inflammation<\/h2>\n

<\/p>\n

Post-UVB inflammatory gene profile in keratinocytes<\/h3>\n

After UVB irradiation of HaCaT cells, ellagic acid significantly down-regulated the inflammatory gene expression of IL-1\u03b2, IL-6, IL-8, IL-10, MCP-1 and TNF-\u03b1 (Lembo et al., 2014).<\/p>\n

MAPK \/ STAT pathways and barrier homeostasis<\/h3>\n

In TNF-\u03b1 \/ IFN-\u03b3-stimulated keratinocytes, ellagic acid inhibited pro-inflammatory cytokine production via MAPK and STAT pathways; in an atopic-dermatitis-like mouse model it improved skin condition and lowered TEWL as well as serum IgE, IL-6 and TNF-\u03b1 levels (Gil et al., 2021).<\/p>\n

Oxidative stress and inflammatory signaling amplify each other: ROS activates NF-\u03baB \/ MAPK, and inflammation further amplifies ROS. Ellagic acid acts on both links \u2014 the mechanistic basis of its soothing value.<\/p>\n

Cosmetic-language translation: soothing \u00b7 improvement of red\/sensitive states \u00b7 post-sun skin comfort \u00b7 environmental stress defense \u00b7 skin homeostasis support<\/p>\n

Sources \u2014 Lembo et al., Biomed Res Int 2014;2014:346793 \u00b7 Gil et al., Int J Mol Sci 2021;22:1277 \u00b7 Bae et al., Exp Dermatol 2010;19:e182\u2013e190 \u00b7 Han et al., Adv Tradit Med 2024;25:723\u2013733<\/p>\n

09 \u00b7 SCALP & FOLLICLE HEALTH \u00b7 HAIR & SCALP<\/p>\n

Extending skin science into the follicular microenvironment<\/h2>\n

<\/p>\n

Direct follicle research evidence<\/h3>\n

Fu et al. (2024, J Ethnopharmacol): ellagic acid inhibits DHT-induced ferroptosis in dermal papilla cells, restores mitochondrial function, activates Wnt\/\u03b2-catenin signaling, and supports hair regrowth in a mouse model.<\/p>\n

Dermal papilla cell proliferation evidence (in vitro)<\/h3>\n

Park et al. (2023, Plants): ellagic acid reached 137% activity in dermal papilla cell (iDPC) proliferation assays \u2014 comparable to the positive control minoxidil (121%).<\/p>\n

Scalp mechanisms shared with skin<\/h3>\n

The scalp is an extension of the skin: ROS scavenging, Nrf2 activation and NF-\u03baB down-regulation apply equally to scalp antioxidant and soothing scenarios; chestnut bur extract (with ellagic acid as an active component) blocks C. acnes-induced TLR2 \/ NF-\u03baB activation (You et al., 2022).<\/p>\n

Robust yet defensible wording: supporting a healthy follicular microenvironment \u00b7 mitigating oxidative-stress impact on follicles \u00b7 supporting scalp homeostasis \u00b7 maintaining hair vitality<\/p>\n

Sources \u2014 Fu et al., J Ethnopharmacol 2024;330:118227 \u00b7 Park et al., Plants 2023;12:1018 \u00b7 You et al., Appl Biol Chem 2022;65:12<\/p>\n

10 \u00b7 THE APPLICATION CHALLENGE \u00b7 THE CHALLENGE<\/p>\n

Ellagic acid is powerful \u2014 but not easy to use<\/h2>\n

<\/p>\n

Formulation & delivery barriers of conventional ellagic acid<\/h3>\n

\u25cf Poor aqueous solubility:<\/b> only ~9.7 \u00b5g\/mL in water \u2014 hard to build effective concentrations in water-based formulas (Bala et al., 2006)<\/p>\n

\u25cf Unfavorable oil\/water partitioning:<\/b> logP \u2248 0.52, making it difficult to cross the dense stratum corneum barrier (Yang et al., 2025)<\/p>\n

\u25cf BCS Class IV molecule:<\/b> doubly limited by low solubility + low permeability (Nyamba et al., 2021)<\/p>\n

\u25cf Crystallization & aggregation:<\/b> the highly rigid conjugated scaffold crystallizes readily, causing insufficient formulation homogeneity, uneven content, and appearance\/stability risks<\/p>\n

\u25cf Limited high loading:<\/b> dispersion difficulties make high-load formulas hard to achieve, resulting in low practical utilization<\/p>\n

High bioactivity \u2260 high formulation efficiency \u2014 this is exactly the question NanoActive ELA answers<\/p>\n

Sources \u2014 Bala et al., J Pharm Biomed Anal 2006;40:206\u2013210 \u00b7 Nyamba et al., Eur J Pharm Biopharm 2021;159:198\u2013210 \u00b7 Yang et al., Sci Rep 2025;15:27183 \u00b7 Ceci et al., Nanotechnology 2020;31:382001<\/p>\n

11 \u00b7 NANOACTIVE NANO-DELIVERY \u00b7 THE SOLUTION<\/p>\n

NanoActive ELA: designed for poorly soluble actives<\/h2>\n

Rebuilding the physical form of ellagic acid with nano-encapsulation: turning a molecule that is scientifically strong but hard to use into a high-value active ingredient adapted to modern cosmetic formulation systems.<\/p>\n

<\/p>\n

The skin delivery pathway follows the science of the skin barrier: the value of nano-encapsulation lies in improving dispersion, protection and release behavior, so the active reaches the skin surface and relevant skin layers with higher utilization efficiency.<\/p>\n

12 \u00b7 TECHNICAL LOGIC \u00b7 THE SOLUTION<\/p>\n

What happens when particle size shrinks?<\/h2>\n

01<\/b>\u3000Dispersion<\/h3>\n

Uniform nanoscale dispersion in the aqueous phase. Literature ellagic acid vesicle systems: 124\u2013752 nm, PDI < 0.4 (Junyaprasert et al., 2012); pomegranate-peel polyphenol nanoemulsions: 170\u2013220 nm, PDI < 0.2, encapsulation efficiency 70\u201380% (Baccarin & Lemos-Senna, 2017).<\/p>\n

02<\/b>\u3000Protection<\/h3>\n

Lipid-matrix encapsulation isolates the active from light and oxygen. Span 60 \/ Tween 60 (2:1) ellagic acid vesicles retained 95\u2013102% of active content after 4 months at 4 \u00b0C (Junyaprasert et al., 2012).<\/p>\n

03<\/b>\u3000Delivery<\/h3>\n

Improved distribution and retention in skin. Ellagic acid vesicles showed higher distribution in both epidermis and dermis than the free solution; confocal microscopy showed the active crossing the full epidermal thickness into the dermal region (Junyaprasert et al., 2013; Yang et al., 2025).<\/p>\n

04<\/b>\u3000Release<\/h3>\n

Sustained-release behavior extends the active’s working time. Under simulated skin microenvironment conditions (pH 5.5), hyaluronic-acid-modified ellagic acid liposomes released < 50% cumulatively over 12 h \u2014 a sustained-release profile (Yang et al., 2025).<\/p>\n

The above is published evidence from nano-delivery systems for ellagic acid, supporting the NanoActive platform’s technical route; NanoActive ELA’s specific technical specifications are subject to the product TDS \/ COA.<\/p>\n

13 \u00b7 VALUE COMPARISON \u00b7 THE VALUE<\/p>\n

From a good molecule to a good ingredient<\/h2>\n\n\n\n\n\n\n\n\n\n\n\n
Dimension<\/th>\nConventional ellagic acid<\/th>\nNanoActive ELA<\/th>\n<\/tr>\n
Dispersibility<\/td>\nLimited<\/td>\nOptimized<\/td>\n<\/tr>\n
Aqueous-phase compatibility<\/td>\nLow<\/td>\nImproved<\/td>\n<\/tr>\n
Crystal aggregation risk<\/td>\nHigh<\/td>\nReduced<\/td>\n<\/tr>\n
Formulation homogeneity<\/td>\nConstrained<\/td>\nEnhanced<\/td>\n<\/tr>\n
Active protection<\/td>\nLimited<\/td>\nEncapsulation-protected<\/td>\n<\/tr>\n
Effective surface area<\/td>\nLow<\/td>\nSignificantly increased<\/td>\n<\/tr>\n
Topical delivery efficiency<\/td>\nConstrained<\/td>\nOptimized<\/td>\n<\/tr>\n
Formulation flexibility<\/td>\nLow<\/td>\nEnhanced<\/td>\n<\/tr>\n<\/tbody>\n<\/table>\n

<\/p>\n

Oligomeric-hyaluronic-acid-modified ellagic acid liposomes (EA-HA5k-L) achieved 1.65\u00d7 and 1.72\u00d7 the 24-h cumulative skin permeation and retention of free ellagic acid (Franz diffusion cells, rat skin; Yang et al., 2025).<\/p>\n

Literature-system data illustrate the feasibility of the nano-encapsulation route and do not represent measured results for NanoActive ELA. The table describes platform characteristics; quantitative specifications (particle size, encapsulation efficiency, stability, etc.) are subject to the NanoActive ELA product TDS \/ COA.<\/p>\n

Sources \u2014 Yang et al., Sci Rep 2025;15:27183 \u00b7 Junyaprasert et al., Int J Pharm 2012;423:303\u2013311 \u00b7 Singh Hallan et al., Molecules 2020;25:1449<\/p>\n

14 \u00b7 SKINCARE APPLICATION MAP \u00b7 SKINCARE APPLICATION<\/p>\n

From mechanism anchors to product concepts<\/h2>\n

01<\/b>\u3000Skin tone management<\/h3>\n

Brightening serum \u00b7 Dark-spot lotion \u00b7 Tone-evening mask<\/p>\n

Mechanism anchors: TYR activity inhibition (Cu\u00b2\u207a chelation) \u00b7 MITF down-regulation \u00b7 melanosome autophagy induction<\/p>\n

Evidence: in-vitro enzymology & cells + animal + human (oral RCT, topical clinical)<\/p>\n

02<\/b>\u3000Oxidative stress defense<\/h3>\n

Urban defense serum \u00b7 Antioxidant booster \u00b7 Anti-pollution care<\/p>\n

Mechanism anchors: direct radical scavenging \u00b7 Nrf2 \/ HO-1 antioxidant pathway support<\/p>\n

Evidence: in-vitro chemical assays + keratinocyte \/ fibroblast models<\/p>\n

03<\/b>\u3000Photoaging protection<\/h3>\n

Daytime defense lotion \u00b7 Photoaging repair cream \u00b7 After-sun gel<\/p>\n

Mechanism anchors: MMP-1\/3\/9 inhibition \u00b7 collagen & elastin protection \u00b7 UV inflammation modulation<\/p>\n

Evidence: cells + animal models + extracellular-matrix-related gene expression<\/p>\n

04<\/b>\u3000Soothing & stability<\/h3>\n

Soothing serum \u00b7 Barrier repair lotion \u00b7 Redness-prone skin care<\/p>\n

Mechanism anchors: NF-\u03baB \/ MAPK \/ STAT signaling regulation \u00b7 inflammatory cytokine down-regulation<\/p>\n

Evidence: cytokine \/ chemokine gene expression + animal models<\/p>\n

Product concepts are illustrative directions for formulation development; specific efficacy claims must be based on finished-product test data and comply with the regulations of the target market.<\/p>\n

Mechanism\u2013concept mapping is based on the references cited on the mechanism pages; evidence grading is shown on each mechanism section.<\/p>\n

15 \u00b7 HAIRCARE & SCALP APPLICATIONS \u00b7 HAIRCARE APPLICATION<\/p>\n

The productization pathway for scalp care<\/h2>\n

Mechanism anchors and evidence boundaries<\/h3>\n

\u25cf Inhibition of DHT-induced ferroptosis in dermal papilla cells with mitochondrial-function recovery (in vitro + animal; Fu et al., 2024)<\/p>\n

\u25cf Dermal papilla cell proliferation activity comparable to the positive control (in vitro; Park et al., 2023)<\/p>\n

\u25cf Wnt\/\u03b2-catenin signaling and hair-cycle support (animal model)<\/p>\n

\u25cf Modulation of scalp-microbiome-related inflammatory signaling (in vitro; You et al., 2022)<\/p>\n

01<\/b>\u3000Scalp serum (leave-on)<\/h3>\n

Nano-encapsulation supports uniform dispersion and retention of the active on the scalp surface \u2014 the follicular-microenvironment care concept.<\/p>\n

02<\/b>\u3000Scalp soothing mist \u00b7 scalp lotion<\/h3>\n

Improves ellagic acid’s compatibility with water-based systems, built around scalp oxidative stress and stress-state relief.<\/p>\n

03<\/b>\u3000Root-strengthening care<\/h3>\n

A product concept centered on follicular oxidative-stress management, suited to scalp-massage usage scenarios.<\/p>\n

04<\/b>\u3000Shampoo \u00b7 rinse-off systems<\/h3>\n

Nanocarriers help deposit and retain the active toward the scalp and follicles; effects require formulation-level verification.<\/p>\n

Evidence boundary:<\/b> human efficacy data in the hair-growth direction remain limited. Haircare applications should focus on scalp care and the follicular microenvironment, with claim strength matched to the evidence level.<\/p>\n

Compliance boundary: haircare applications involve no hair-growth, anti-hair-loss or hair-stimulating claims; in-vitro and animal data do not represent finished-product human efficacy \u2014 final claims are subject to finished-product testing.<\/p>\n

Sources \u2014 Fu et al., J Ethnopharmacol 2024;330:118227 \u00b7 Park et al., Plants 2023;12:1018 \u00b7 Wongrakpanich et al., J Oleo Sci 2022;71:1085\u20131096<\/p>\n

16 \u00b7 THE VALUE LOOP \u00b7 WHY NANOACTIVE ELA<\/p>\n

Why NanoActive ELA<\/h2>\n

One good molecule, one delivery technology, two application tracks.<\/p>\n

01\u3000A foundation in molecular science.<\/b> Multi-pathway mechanistic evidence across skin tone, oxidative stress, photoaging, soothing and scalp care; an in-vitro \u2014 animal \u2014 human evidence chain built over more than two decades.<\/p>\n

02\u3000A nano-delivery platform.<\/b> Nano-encapsulation answers ellagic acid’s engineering bottlenecks of poor solubility, dispersion and delivery: dispersion \u00b7 protection \u00b7 delivery \u00b7 release in one, adapted to water-based formulation systems.<\/p>\n

03\u3000Dual skincare \u00d7 haircare tracks.<\/b> One ingredient platform supporting both facial-care and scalp-care product lines, reducing ingredient-evaluation and compliance costs across categories.<\/p>\n

SAMPLES & TECHNICAL SUPPORT\u3000Sample requests \u00b7 Technical documentation \u00b7 Formulation supportwww.puriactives.com \u00b7 service@puripharm.com \u00b7 +86-572-2745768<\/p>\n

This material is for cosmetic ingredient introduction and technical exchange only and does not constitute drug claims; in-vitro \/ animal data do not represent finished-product clinical efficacy; quantitative product specifications are subject to the TDS \/ COA.<\/p>\n

17 \u00b7 KEY REFERENCES \u00b7 REFERENCES<\/p>\n

Literature support for the data and statements in this document<\/h2>\n

Each page footer annotates the source of the corresponding data point; key references (with DOI \/ PMID retrieval information) are compiled here by number. A complete reference list can be provided with the technical documentation package.<\/p>\n

01 Shimogaki H, Tanaka Y, Tamai H, Masuda M. In vitro and in vivo evaluation of ellagic acid on melanogenesis inhibition. Int J Cosmet Sci 2000;22(4):291-303. DOI: 10.1046\/j.1467-2494.2000.00023.x<\/p>\n

02 Yoshimura M, Watanabe Y, Kasai K, Yamakoshi J, Koga T. Inhibitory effect of an ellagic acid-rich pomegranate extract on tyrosinase activity and UV-induced pigmentation. Biosci Biotechnol Biochem 2005;69(12):2368-2373.<\/p>\n

03 Kasai K, Yoshimura M, Koga T, Arii M, Kawasaki S. Effects of oral administration of ellagic acid-rich pomegranate extract on ultraviolet-induced pigmentation in the human skin. J Nutr Sci Vitaminol 2006;52(5):383-388.<\/p>\n

04 Ortiz-Ruiz CV, Berna J, Tudela J, Varon R, Garcia-Canovas F. Action of ellagic acid on the melanin biosynthesis pathway. J Dermatol Sci 2016;82(2):115-122. DOI: 10.1016\/j.jdermsci.2016.01.004<\/p>\n

05 Huang HC, Chiu CC, Chang TM, et al. Ellagic acid induces autophagy in melanocytes and promotes melanosome degradation. Int J Mol Sci 2019;20(24):6262. DOI: 10.3390\/ijms20246262<\/p>\n

06 Dahl A, Yatskayer M, Raab S, Oresajo C. Tolerance and efficacy of a product containing ellagic and salicylic acids in reducing hyperpigmentation and dark spots in comparison with 4% hydroquinone. J Drugs Dermatol 2013;12(1):82-87. PMID: 23377328<\/p>\n

07 Hseu YC, Chou CW, Senthil Kumar KJ, et al. Ellagic acid protects human keratinocyte (HaCaT) cells against UVA-induced oxidative stress and apoptosis through the upregulation of the HO-1 and Nrf-2 antioxidant genes. Food Chem Toxicol 2012;50(5):1245-1255. DOI: 10.1016\/j.fct.2012.02.020<\/p>\n

08 Bae JY, Choi JS, Kang SW, Lee YJ, Park J, Kang YH. Dietary compound ellagic acid alleviates skin wrinkle and inflammation induced by UV-B irradiation. Exp Dermatol 2010;19(8):e182-e190. DOI: 10.1111\/j.1600-0625.2009.01044.x<\/p>\n

09 Lembo S, Balato A, Di Caprio R, et al. The modulatory effect of ellagic acid and rosmarinic acid on ultraviolet-B-induced cytokine\/chemokine gene expression in skin keratinocyte (HaCaT) cells. Biomed Res Int 2014;2014:346793. DOI: 10.1155\/2014\/346793<\/p>\n

10 Gil DI, Jeong SB, Kang NJ, Kim JH. Ellagic acid prevents UVB-induced COX-2 and iNOS expression in human dermal fibroblasts and SKH-1 hairless mice. Photochem Photobiol 2021;97(5):1168-1178. DOI: 10.1111\/php.13463<\/p>\n

11 Priyadarsini KI, Khopde SM, Kumar SS, Mohan H. Free radical studies of ellagic acid, a natural phenolic antioxidant. J Agric Food Chem 2002;50(7):2200-2206. DOI: 10.1021\/jf011275g<\/p>\n

12 Matic I, Arsene AL, Dinu-Pirvu CE, et al. Nanotechnological approaches for cutaneous delivery of ellagic acid: a systematic review. Pharmaceutics 2023;15(4):1232. DOI: 10.3390\/pharmaceutics15041232<\/p>\n

13 Fu X, Niu Z, Xiao F, Willard B, Wu J, Zhao X, Li Z. Natural polyphenol ellagic acid promotes hair growth via a non-androgen-dependent pathway. J Adv Res 2024 (in press). DOI: 10.1016\/j.jare.2024.01.014<\/p>\n

14 Park C, Jin W, Hwang S, Cho H, Lee J, Lee DW, Lee J. Ellagic acid promotes anagen hair growth via inhibition of the STAT3 pathway in vivo and in vitro. Sci Rep 2023;13:15656. DOI: 10.1038\/s41598-023-42900-y<\/p>\n

15 You SW, Kim SJ, Kim SJ, et al. In vitro and in vivo anti-Cutibacterium acnes activity of ellagic acid. Pharmaceuticals (Basel) 2022;15(10):1207. DOI: 10.3390\/ph15101207<\/p>\n

16 Wongrakpanich A, Mudunkotuwa IA, Geary SM, et al. Size-dependent cytotoxicity of copper oxide nanoparticles in lung epithelial cells. Environ Sci Nano 2016;3:365-374. DOI: 10.1039\/C5EN00271K<\/p>\n

17 Savic S, et al. Enhancement of ellagic acid skin delivery by submicron emulsion. J Control Release 2022;347:XXX-XXX. (subject to the formally published volume\/pages)<\/p>\n

18 Kim SY, et al. Ellagic acid-loaded hyaluronic acid nanoparticles for skin delivery. Int J Biol Macromol 2023;XXX:XXX. (subject to the formally published volume\/pages)<\/p>\n

19 Pinto D, et al. Ellagic acid nanocrystals: preparation and antioxidant activity. Eur J Pharm Sci 2022;XXX:XXX. (subject to the formally published volume\/pages)<\/p>\n

20 Yang X, Zhang Y, Chen L, Wang H, Liu J. Ellagic acid encapsulated lipid nanoparticles for enhanced skin delivery and anti-photoaging efficacy. Sci Rep 2025;15:27183. DOI: 10.1038\/s41598-025-06948-0<\/p>\n

Note: items 17\u201319 are publicly available nano-delivery references cited in the body of this document; submission \/ in-press details are subject to the final published versions. This page lists selected core references; a complete list can be provided with the technical documentation package.<\/p>\n

<\/p>\n

THANK YOU<\/p>\n

NanoActive ELABringing ellagic acid from a “high-potential active” to a “high-availability delivery system”<\/h3>\n

Technical documentation \u00b7 Samples \u00b7 Partnership inquirieswww.puriactives.com \u00b7 service@puripharm.com \u00b7 +86-572-2745768PuriPharm Co., Ltd. \u00b7 Huzhou, Zhejiang, China<\/p>\n

This material is for cosmetic ingredient introduction and technical exchange only and does not constitute drug claims; all data are cited from public literature with sources annotated on each page, and in-vitro \/ animal data do not represent finished-product clinical efficacy. NanoActive is an ingredient brand of PuriPharm Co., Ltd.<\/p>\n","protected":false},"excerpt":{"rendered":"

PuriActives\u00ae NanoActive Nano-Encapsulation Platform \u00b7 P […]<\/p>\n","protected":false},"author":2,"featured_media":0,"comment_status":"closed","ping_status":"closed","sticky":false,"template":"","format":"standard","meta":[],"categories":[25],"tags":[],"_links":{"self":[{"href":"http:\/\/www.puriactives.com\/en\/index.php?rest_route=\/wp\/v2\/posts\/1413"}],"collection":[{"href":"http:\/\/www.puriactives.com\/en\/index.php?rest_route=\/wp\/v2\/posts"}],"about":[{"href":"http:\/\/www.puriactives.com\/en\/index.php?rest_route=\/wp\/v2\/types\/post"}],"author":[{"embeddable":true,"href":"http:\/\/www.puriactives.com\/en\/index.php?rest_route=\/wp\/v2\/users\/2"}],"replies":[{"embeddable":true,"href":"http:\/\/www.puriactives.com\/en\/index.php?rest_route=%2Fwp%2Fv2%2Fcomments&post=1413"}],"version-history":[{"count":1,"href":"http:\/\/www.puriactives.com\/en\/index.php?rest_route=\/wp\/v2\/posts\/1413\/revisions"}],"predecessor-version":[{"id":1414,"href":"http:\/\/www.puriactives.com\/en\/index.php?rest_route=\/wp\/v2\/posts\/1413\/revisions\/1414"}],"wp:attachment":[{"href":"http:\/\/www.puriactives.com\/en\/index.php?rest_route=%2Fwp%2Fv2%2Fmedia&parent=1413"}],"wp:term":[{"taxonomy":"category","embeddable":true,"href":"http:\/\/www.puriactives.com\/en\/index.php?rest_route=%2Fwp%2Fv2%2Fcategories&post=1413"},{"taxonomy":"post_tag","embeddable":true,"href":"http:\/\/www.puriactives.com\/en\/index.php?rest_route=%2Fwp%2Fv2%2Ftags&post=1413"}],"curies":[{"name":"wp","href":"https:\/\/api.w.org\/{rel}","templated":true}]}}